Quantitative Proteomic and Phosphoproteomic Analyses Reveal a Role of Death-Associated Protein Kinase 1 in Regulating Hippocampal Synapse

Tian, Yuan; Zheng, Xiaoqing; Li, Ruomeng; Hu, Li; Shui, Xindong; Wang, Long; Chen, Dongmei; Lee, Tae Ho; Zhang, Tao

doi:10.1007/s12035-023-03674-4

Cited by 1 publication

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high abundance of DAPK1 in adult hippocampal tissues and in particular its enrichment in dendritic spines indicate that DAPK1 may possess important physiological functions in regulating synaptic structure and plasticity [ 73 , 164 ]. This has been confirmed by our recent quantitative proteomic and phosphoproteomic analyses of hippocampal tissues from WT and DAPK1 KO mice [ 178 ]. Glutamate receptors are one of the major modulators of the synaptic Ca 2+ influx in neurons [ 179 ].…”

Section: The Role Of Dapk1 In Alzheimer’s Core Pathologiessupporting

confidence: 71%

Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease

Zhang,

Kim,

Lee

2024

Transl Neurodegener

Self Cite

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most prevalent form of dementia in the elderly and represents a major clinical challenge in the ageing society. Neuropathological hallmarks of AD include neurofibrillary tangles composed of hyperphosphorylated tau, senile plaques derived from the deposition of amyloid-β (Aβ) peptides, brain atrophy induced by neuronal loss, and synaptic dysfunctions. Death-associated protein kinase 1 (DAPK1) is ubiquitously expressed in the central nervous system. Dysregulation of DAPK1 has been shown to contribute to various neurological diseases including AD, ischemic stroke and Parkinson’s disease (PD). We have established an upstream effect of DAPK1 on Aβ and tau pathologies and neuronal apoptosis through kinase-mediated protein phosphorylation, supporting a causal role of DAPK1 in the pathophysiology of AD. In this review, we summarize current knowledge about how DAPK1 is involved in various AD pathological changes including tau hyperphosphorylation, Aβ deposition, neuronal cell death and synaptic degeneration. The underlying molecular mechanisms of DAPK1 dysregulation in AD are discussed. We also review the recent progress regarding the development of novel DAPK1 modulators and their potential applications in AD intervention. These findings substantiate DAPK1 as a novel therapeutic target for the development of multifunctional disease-modifying treatments for AD and other neurological disorders.

show abstract